PREVIEW ASH 2026 — New Orleans, Dec 12–15: the abstracts hematologists are watching, top voices and trial buzz See the ASH 2026 preview →
KOL Pulse · AI-Native Trial Intelligence

TroFuse-015 Trial

TroFuse-015 (NCT06356311) is Merck’s Phase 3 trial of sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate licensed from Kelun-Biotech, versus physician’s choice chemotherapy in 473 patients with third-line or later gastroesophageal adenocarcinoma. On November 20, 2026, Merck reported the primary overall survival endpoint was met; PFS by central review was not. No hazard ratio has been released.

⚠ Investigational · not FDA approved Phase 3 · NCT06356311 3L+ gastroesophageal adenocarcinoma n=473 · vs physician’s choice Topline · Nov 20, 2026
See the KOL Reaction

TroFuse-015 Key Takeaways

Design

Global, randomized, open-label Phase 3. 473 patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma after at least two prior lines of therapy. Sac-TMT vs treatment of physician’s choice (trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel). Enrollment regardless of HER2 status; TROP2 tested centrally for stratification. ClinicalTrials.gov NCT06356311

Efficacy (topline only)

✅ Overall survival (primary) met at the final analysis: statistically significant and clinically meaningful improvement vs physician’s choice, generally consistent regardless of TROP2 expression. ❌ PFS by blinded independent central review (secondary) not met. Objective response rate nominally favored sac-TMT but was not formally tested. No hazard ratio, medians or p-values have been released. Source: Merck press release, Nov 20, 2026

Safety

Merck reported the safety profile was consistent with previous studies of sac-TMT, with no new safety signals. No adverse-event rates have been released. Source: Merck press release

Regulatory

⚠ Investigational. Sac-TMT is not approved by the FDA in any indication and is not approved for gastroesophageal cancer anywhere. It is approved in China in other indications (Kelun-Biotech). Merck plans to discuss the data with regulators and present them at an upcoming medical meeting. Sac-TMT is a different drug from sacituzumab govitecan (Trodelvy).

Free Access · KOL Pulse Intelligence

Track oncology’s top KOLs in your specialty

Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:

  • ✓Enhanced KOL profiles
  • ✓Pharma influence & potential advisory-board patterns
  • ✓2025 Open Payments financial analysis
  • ✓Social-media sentiment & trend signals
Get free access — pick your specialty
Choose the tumor types you follow. No cost, unsubscribe anytime.

Physicians Discussing TroFuse-015

Kohei shitara
Kohei shitara
10.8K impressions
Paolo Tarantino
Paolo Tarantino
6.1K impressions
Allan Pereira, MD, PhD
Allan Pereira, MD, PhD
675 impressions
Sunnie Kim, MD
Sunnie Kim, MD
587 impressions
Wafik S. El-Deiry, MD, PhD, FACP
Wafik S. El-Deiry, MD, PhD, FACP
450 impressions
Niklas Klümper
Niklas Klümper
189 impressions

Physician Reactions to the Topline

Full, verbatim posts by physicians, linked to the originals, ordered by views. No slides exist yet: the data have not been presented.

Kohei shitara@KoheiShitara
𝕏

Phase 3 TROFUSE-015: Sac-TMT, a TROP2-directed ADC, improved OS in 3L+ gastroesophageal adenocarcinoma, but did not meet PFS. Looking forward to the full data presentation and further discussion! https://t.co/5KXIxqUBjf

10.8K views 83 likes20 RT 2026-11-20
Paolo Tarantino@PTarantinoMD
𝕏

Interesting to see yet another ADC improving OS, but not PFS, in gastric cancer. Certainly preferable to the opposite scenario, which we see all too often. https://t.co/FEhyniRkI5

6.1K views 63 likes8 RT 2026-11-21
Allan Pereira, MD, PhD@DrAllanPereira
𝕏

👁️ TroFuse-015 Phase 3 (Merck press release) 🎯 Gastroesophageal adenocarcinoma after 2 or more prior lines 👥 473 patients randomised 💊 Sacituzumab tirumotecan (TROP2 ADC) vs physician's choice: trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel ✅ OS primary endpoint met at final analysis ❌ PFS by central review not met ⚠️ No HR or medians released yet A third-line gastroesophageal trial that wins on overall survival deserves attention. But... 1st - What is the size of the OS benefit? 2nd - how an OS win sits with a PFS miss (which can point to post-progression effects or crossover rather than tumour control). 3rd- The benefit being independent of TROP2 expression would also mean no biomarker test before treatment. So many ADCs these days... Do not confuse sac-TMT with sacituzumab govitecan: different payload, different linker. Also, Izalontamab brengitecan (PANKU Esophagus01) was for 2nd line ESCC. #GIOnc #GastricCancer #ADC #TROP2 https://t.co/rBERYEISVq

675 views 9 likes1 RT 2026-11-21
Sunnie Kim, MD@SunnieSKim
𝕏

@KoheiShitara On the heels of the sone-ve data also showing an OS but not a PFS benefit in refractory gastric ca. Looking forward to seeing the data soon!

587 views 4 likes0 RT 2026-11-21
Wafik S. El-Deiry, MD, PhD, FACP@weldeiry
𝕏

Sacituzumab Tirumotecan Improves OS in 3L+ Gastroesophageal Cancer https://t.co/ct5ii0arMQ

450 views 0 likes0 RT 2026-11-21
Niklas Klümper@niklas_kluemper
𝕏

🎯 Another phase III OS win for ADCs! TroFuse-015 (n=473): TROP2 ADC sacituzumab tirumotecan improves OS vs physician’s choice in ≥3L gastroesophageal cancer. But PFS endpoint missed. No HRs or medians disclosed yet. Intriguing OS–PFS discordance! Full data needed. https://t.co/QWq6tceZAy @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3

189 views 4 likes3 RT 2026-11-21

Trial Methodology & Results

Study Design

Randomized, open-label, multicenter global Phase 3 (outcomes assessor masked). Actual enrollment 473. Randomization stratified by TROP2 expression, geographic region and ECOG performance status (OncLive, CancerNetwork).

Population

Advanced unresectable or metastatic gastric, GEJ or esophageal adenocarcinoma after ≥2 prior chemotherapy and/or immunotherapy regimens; any HER2 status (HER2+ must have had trastuzumab where available); ECOG 0–1; tissue for central TROP2 testing. Prior lines included a fluoropyrimidine and a platinum doublet (OncLive).

Intervention

Sac-TMT 4 mg/kg IV on days 1, 15 and 29 of each 42-day cycle.

Comparator

Physician’s choice: trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel.

Endpoints

Primary: overall survival. Secondary: PFS (BICR), objective response rate, duration of response, safety.

Sponsor

Merck Sharp & Dohme LLC. Sac-TMT licensed from Kelun-Biotech (Merck holds rights outside Greater China).

Overall Survival — primary endpoint met

At the final analysis, sac-TMT showed a statistically significant and clinically meaningful improvement in OS vs physician’s choice; results were generally consistent across subgroups regardless of TROP2 expression. Merck has not disclosed the hazard ratio, confidence interval, p-value or median OS.

OS met · magnitude not yet disclosed
Source: Merck press release, Nov 20, 2026 · ClinicalTrials.gov

Progression-Free Survival & Response — secondary

PFS by blinded independent central review did not meet its endpoint. ORR nominally favored sac-TMT but was not formally tested under the prespecified analysis plan. No PFS or ORR figures have been released.

Source: Merck press release, Nov 20, 2026

Safety

Consistent with previous studies of sac-TMT; no new safety signals (Merck). Rates not yet disclosed.

Source: Merck press release

Clinical Implications

⚠ Investigational: sac-TMT has no FDA approval in any indication. TroFuse-015 is the second positive Phase 3 readout for sac-TMT in Merck’s TroFuse program, after TroFuse-005 in endometrial cancer. Physicians are waiting for the size of the OS benefit and an explanation of the OS–PFS discordance before judging its place in third-line gastroesophageal cancer.

Source: Merck press release

TroFuse-015 in the News

Oncology media posts on X:

TroFuse-015 FAQ

What is the TroFuse-015 trial?

TroFuse-015 (NCT06356311, MK-2870-015) is a global, randomized, open-label Phase 3 trial sponsored by Merck (MSD) that compared sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate, with treatment of physician's choice in 473 patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma (gastric, gastroesophageal junction or esophageal) who had received at least two prior lines of therapy.

What were the TroFuse-015 results?

Merck announced on November 20, 2026 that TroFuse-015 met its primary endpoint of overall survival at the final analysis, with a statistically significant and clinically meaningful improvement versus treatment of physician's choice, generally consistent across subgroups regardless of TROP2 expression. The secondary endpoint of progression-free survival by blinded independent central review was not met. Objective response rate nominally favored sac-TMT but was not formally tested. Merck has not released a hazard ratio, medians or p-values; full data will be presented at an upcoming medical meeting.

What was the comparator in TroFuse-015?

Treatment of physician's choice: trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Sac-TMT was given at 4 mg/kg intravenously on days 1, 15 and 29 of each 42-day cycle (ClinicalTrials.gov NCT06356311).

Is sacituzumab tirumotecan FDA approved?

No. Sacituzumab tirumotecan is investigational in the United States and has no FDA approval in any indication, including gastroesophageal cancer. It is approved in China in other indications, where it was developed by Kelun-Biotech, which licensed it to Merck outside Greater China. Merck said it will discuss the TroFuse-015 data with regulatory authorities.

Is sac-TMT the same drug as sacituzumab govitecan?

No. Both target TROP2 with the same sacituzumab antibody, but they are different drugs: sacituzumab tirumotecan (sac-TMT, MK-2870) carries a belotecan-derived topoisomerase I inhibitor payload (KL610023) attached with different conjugation chemistry, while sacituzumab govitecan (Trodelvy) carries SN-38.

Key KOL Sentiments — TroFuse-015

KOLComment (verbatim)Sentiment
Kohei shitara Phase 3 TROFUSE-015: Sac-TMT, a TROP2-directed ADC, improved OS in 3L+ gastroesophageal adenocarcinoma, but did not meet PFS. Looking forward to the full data presentation and further discussion! https://t.co/5KXIxqUBjf Positive
Paolo Tarantino Interesting to see yet another ADC improving OS, but not PFS, in gastric cancer. Certainly preferable to the opposite scenario, which we see all too often. https://t.co/FEhyniRkI5 Positive
Niklas Klümper 🎯 Another phase III OS win for ADCs! TroFuse-015 (n=473): TROP2 ADC sacituzumab tirumotecan improves OS vs physician’s choice in ≥3L gastroesophageal cancer. But PFS endpoint missed. No HRs or medians disclosed yet. Intriguing OS–PFS discordance! Full data needed. https://t.co/QWq6tceZAy @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3 Positive
Allan Pereira, MD, PhD 👁️ TroFuse-015 Phase 3 (Merck press release) 🎯 Gastroesophageal adenocarcinoma after 2 or more prior lines 👥 473 patients randomised 💊 Sacituzumab tirumotecan (TROP2 ADC) vs physician's choice: trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel ✅ OS primary endpoint met at final analysis ❌ PFS by central review not met ⚠️ No HR or medians released yet A third-line gastroesophageal trial that wins on overall survival deserves attention. But... 1st - What is the size of the OS benefit? 2nd - how an OS win sits with a PFS miss (which can point to post-progression effects or crossover rather than tumour control). 3rd- The benefit being independent of TROP2 expression would also mean no biomarker test before treatment. So many ADCs these days... Do not confuse sac-TMT with sacituzumab govitecan: different payload, different linker. Also, Izalontamab brengitecan (PANKU Esophagus01) was for 2nd line ESCC. #GIOnc #GastricCancer #ADC #TROP2 https://t.co/rBERYEISVq Neutral
Sunnie Kim, MD @KoheiShitara On the heels of the sone-ve data also showing an OS but not a PFS benefit in refractory gastric ca. Looking forward to seeing the data soon! Neutral
Wafik S. El-Deiry, MD, PhD, FACP Sacituzumab Tirumotecan Improves OS in 3L+ Gastroesophageal Cancer https://t.co/ct5ii0arMQ Neutral